Insider · CIK 0001486672
Kenneth Allen Myszkowski
Files at ARWR (ARROWHEAD PHARMACEUTICALS, INC.). First filing Jan 7, 2025, latest Jan 7, 2025.
In brief
Kenneth Allen Myszkowski files SEC Form 4 as CFO at ARWR (ARROWHEAD PHARMACEUTICALS, INC.). Since Jan 7, 2025, Kenneth Allen Myszkowski has reported 0 open-market buys worth $0 and 1 open-market sell worth $893k, the latest filed on Jan 7, 2025.
A track record needs three past buys with six months of prices behind them; Kenneth Allen Myszkowski has 0, so none is measured yet.
The newest scored trade: sold $893k of ARWR on Jan 6, 2025, filed Jan 7, 2025, scored 41 (moderate), under a 10b5-1 plan.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ARWR: ARROWHEAD PHARMACEUTICALS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 41Moderate | ARROWHEAD PHARMACEUTICALS, INC. | $893k 45,167 shares | -9% | +10% from low-26% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jul 10, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | 40,000 0.03% of outstanding | $762k | Jul 10, 2025 | none |
| Jan 7, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | 8,000 0.01% of outstanding | $158k | Jan 7, 2025 | $539k |
| Jan 7, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | 10,000 0.01% of outstanding | $197k | Jan 7, 2025 | $539k |
| Jan 6, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | 5,817 0.00% of outstanding | $115k | Jan 6, 2025 | none |
| Jan 6, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | 6,287 0.01% of outstanding | $124k | Jan 6, 2025 | none |
| Jan 6, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | 9,255 0.01% of outstanding | $183k | Jan 6, 2025 | none |
| Jan 6, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | 5,817 0.00% of outstanding | $115k | Jan 6, 2025 | none |
| Mar 6, 2024 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | 40,000 0.03% of outstanding | $1.4M | Mar 6, 2024 | $568k |
| Jan 5, 2024 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | 16,104 0.01% of outstanding | $568k | Jan 5, 2024 | none |
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 4, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | AGrant or award Common Stock10b5-1 | +100,000 | $0.00 | $0 | 500,600 | Jan 7, 2025 |
| Jan 6, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -17,765 | $19.68 | $350k | 482,835 | Jan 7, 2025 |
| Jan 6, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -9,402 | $20.10 | $189k | 473,433 | Jan 7, 2025 |
| Jan 7, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -8,000 | $19.70 | $158k | 465,433 | Jan 7, 2025 |
| Jan 7, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -10,000 | $19.69 | $197k | 455,433 | Jan 7, 2025 |
Questions about Kenneth Allen Myszkowski
Answered from the filings on this page, as of the latest one.
Is Kenneth Allen Myszkowski buying or selling?
Not in the last 12 months. Kenneth Allen Myszkowski's latest open-market trade on SEC Form 4 was sold $893k of ARWR on Jan 6, 2025.
How did Kenneth Allen Myszkowski's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Kenneth Allen Myszkowski has 0.
Where does Kenneth Allen Myszkowski file Form 4?
Kenneth Allen Myszkowski has filed Form 4 at ARWR (ARROWHEAD PHARMACEUTICALS, INC.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.